Recent Advances in Nanoparticles for Mucosal Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 2367

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
Interests: film technology; HIV/ADS prevention; mucoadhesion; topical pre-exposure prophylaxis; vaginal drug delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
Interests: drug controlled release; HIV; microbicides; mucoadhesiveness; natural polymers; vaginal route
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug delivery is possible through various administration routes, and most of them involve passage through mucous membranes (from absorption through the digestive tract after oral administration, to absorption through the buccal, sublingual, nasal, ocular, vaginal, rectal mucosa passageways, etc.). However, the characteristics of all the above-mentioned mucous membranes can differ greatly, in addition to their capacity for drug absorption. This implies the need for continuous research to optimize mucosal drug delivery systems.

In recent decades, nanomedicines have made it possible to significantly improve therapeutics, and mucosal delivery is no exception. Thus, nanotechnology has been harnessed to reach a specific therapeutic target, to increase the retention of formulations at the site of action or even to promote their permeability through mucosal tissue.

All articles that explore the use of nanoparticles for mucosal drug delivery, whatever their therapeutic target, are welcome in this Special Issue. This includes articles that propose the innovative development of nanoparticles, as well as those that deepen the results of its administration, and also bibliographic reviews that update the current state of the art in this field.

Dr. Fernando Notario-Pérez
Dr. Roberto Ruiz-Caro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioavailability enhancement
  • controlled release
  • mucoadhesion
  • mucopenetration
  • nanocarriers
  • nanomedicines
  • targeted drug delivery
  • topical drug delivery
  • vaccine delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

34 pages, 2873 KiB  
Review
Chitosan Nanoparticles for Intranasal Drug Delivery
by Hossein Omidian, Erma J. Gill, Sumana Dey Chowdhury and Luigi X. Cubeddu
Pharmaceutics 2024, 16(6), 746; https://doi.org/10.3390/pharmaceutics16060746 - 31 May 2024
Cited by 1 | Viewed by 1891
Abstract
This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by [...] Read more.
This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by facilitating drug transport across the blood–brain barrier. Despite substantial advancements in targeted delivery and vaccine efficacy, challenges remain in scalability, regulatory approval, and transitioning from preclinical studies to clinical applications. The future of chitosan-based nanomedicines hinges on advancing clinical trials, fostering interdisciplinary collaboration, and innovating in nanoparticle design to overcome these hurdles and realize their therapeutic potential. Full article
(This article belongs to the Special Issue Recent Advances in Nanoparticles for Mucosal Drug Delivery)
Show Figures

Figure 1

Back to TopTop